ArticleOncotarget2018
Racial differences in endometrial cancer molecular portraits in The Cancer Genome Atlas.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials.Frontiers in immunology · 2025Pooled it
- PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.Journal of gynecologic oncology · 2024Trial
- Factors influencing care for patients with gynecologic malignancies from culturally and linguistically diverse backgrounds: a questionnaire study (iCALD-2).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Design and evaluation of a custom circulating tumour DNA assay to detect endometrial cancer recurrence.NPJ precision oncology · 2026Article
- In- vitro assessment of the anti- malarial potential of Alpha Onocerin; cytotoxicity and hemolytic effect, multi-stage activity and molecular docking.BMC pharmacology & toxicology · 2026Article
- Ancestrally Diverse Autologous Patient-Derived Organoid-Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer.Cancer research communications · 2026Article
- Comparing self-reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models.Molecular oncology · 2025Article
- Epidemiological and Histopathological Characterization of Endometrial Carcinoma: A Retrospective Cohort from Romania.Diagnostics (Basel, Switzerland) · 2025Article
- Computational image and molecular analysis reveal unique prognostic features of immune architecture in African Versus European American women with endometrial cancer.NPJ precision oncology · 2025Article
- Pathogenic germline variants among women with uterine cancer by ancestry: A commercial laboratory collaborative research registry study.Gynecologic oncology · 2025Article
- Epigenetic mechanisms underlying endometrial cancer outcomes: race-specific patterns of DNA methylation associated with molecular subtypes and survival.Carcinogenesis · 2025Article
- An elevated rate of whole-genome duplications in cancers from Black patients.Nature communications · 2024Article
- Single-nuclei sequencing of uterine serous carcinoma reveals racial differences in immune signaling.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.Gynecologic oncology · 2024Article
- Landscape and Saturation Analysis of Mutations Associated With Race in Cancer Genomes by Clinical Sequencing.The oncologist · 2024Article
- Changing trends in the disease burden of uterine cancer globally from 1990 to 2019 and its predicted level in 25 years.Frontiers in oncology · 2024Article
- Epidemiology, site-specific characteristics and survival of carcinosarcoma: a retrospective study based on SEER database.BMJ open · 2023Article
- Article
- Racial and ethnic differences in tumor characteristics among endometrial cancer patients in an equal-access healthcare population.Cancer causes & control : CCC · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is now the most prevalent gynaecological malignancy in the Western world. Black or African American women (BoAA) have double the mortality of Caucasian women, and their tumours tend to be of higher grade. Despite these disparities, little is known regarding the mutational landscape of EC between races. Hence, we wished to investigate the molecular features of ECs within The Cancer Genome Atlas (TCGA) dataset by racial groupings. In total 374 Caucasian, 109 BoAA and 20 Asian patients were included in the analysis. Asian women were diagnosed at younger age, 54.2 years versus 64.5 years for Caucasian and 64.9 years for BoAA women (OR 3.432; p=0.011); BoAA women were more likely to have serous type tumors (OR 2.061; p=0.008). No difference in overall survival was evident. The most frequently mutated gene in Caucasian and Asian tumours was
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.